ArticleDiscover oncology2026
Baseline vitamin D levels and progression-free survival in patients with HR+/HER2-metastatic breast cancer treated with ribociclib: a retrospective single-center analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D has been implicated in cancer biology and immunity, yet its prognostic relevance in patients receiving CDK4/6 inhibitors remains unclear.
methodsWe retrospectively analyzed 89 patients with HR+/HER2 - metastatic breast cancer (MBC) treated with ribociclib plus endocrine therapy between January 2018 and December 2023 at a single institution. Baseline serum 25-hydroxyvitamin D3 [25(OH)D3] levels obtained prior to treatment initiation were categorized as deficient (≤ 20 ng/mL) or sufficient (> 20 ng/mL). The primary endpoint was progression-free survival (PFS). Survival outcomes were assessed using Kaplan-Meier estimates, log-rank tests, and Cox proportional hazards models.
resultsThe median baseline vitamin D level was 19 ng/mL. The overall median PFS was 36 months. Patients with sufficient vitamin D had not reached median PFS, whereas those with deficiency had a median PFS of 14 months (95% confidence interval (CI), 12.6-15.3; p < 0.001). At 24 months, PFS was 100% in the sufficient group versus 23.1% in the deficient group. In multivariate Cox analysis, baseline vitamin D deficiency remained associated with inferior PFS (HR 32.33, 95% CI 6.90-151.5; p < 0.001), although the wide confidence intervals should be interpreted cautiously given the limited number of progression events in the vitamin D-sufficient subgroup. Other clinicopathological variables did not show statistically significant associations with PFS.
conclusionBaseline vitamin D status was associated with progression-free survival outcomes in patients with HR+/HER2 - metastatic breast cancer receiving ribociclib-based therapy. Patients with sufficient vitamin D levels demonstrated longer progression-free survival compared with those with vitamin D deficiency. However, given the retrospective design, limited sample size, residual confounding, and substantial censoring, these findings should be interpreted cautiously and considered exploratory and hypothesis-generating. Larger prospective studies are required to validate these observations and to clarify the potential clinical relevance of baseline vitamin D status in patients treated with CDK4/6 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.